Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy

dc.creatorRocha, Luisa
dc.creatorLizette Frías Soria , Christian
dc.creatorOrtiz, José G.
dc.creatorAuzmendi, Jerónimo Andrés
dc.creatorLazarowski, Alberto
dc.date.accessioned2021-09-13T12:48:00Z
dc.date.accessioned2022-10-15T13:02:56Z
dc.date.available2021-09-13T12:48:00Z
dc.date.available2022-10-15T13:02:56Z
dc.date.created2021-09-13T12:48:00Z
dc.date.issued2020-01
dc.identifierRocha, Luisa; Lizette Frías Soria , Christian; Ortiz, José G.; Auzmendi, Jerónimo Andrés; Lazarowski, Alberto; Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy; Wiley Blackwell Publishing, Inc; Epilepsia Open; 5; 1; 1-2020; 36-49
dc.identifier2470-9239
dc.identifierhttp://hdl.handle.net/11336/140176
dc.identifier2470-9239
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4389089
dc.description.abstractCannabis has been considered as a therapeutic strategy to control intractable epilepsy. Several cannabis components, especially cannabidiol (CBD), induce antiseizure effects. However, additional information is necessary to identify the types of epilepsies that can be controlled by these components and the mechanisms involved in these effects. This review presents a summary of the discussion carried out during the 2nd Latin American Workshop on Neurobiology of Epilepsy entitled “Cannabinoid and epilepsy: myths and realities.” This event was carried out during the 10th Latin American Epilepsy Congress in San José de Costa Rica (September 28, 2018). The review focuses to discuss the use of CBD as a new therapeutic strategy to control drug-resistant epilepsy. It also indicates the necessity to consider the evaluation of unconventional targets such as P-glycoprotein, to explain the effects of CBD in drug-resistant epilepsy.
dc.languageeng
dc.publisherWiley Blackwell Publishing, Inc
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/epi4.12376
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1002/epi4.12376
dc.rightshttps://creativecommons.org/licenses/by/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCANNABIDIOL
dc.subjectCANNABIS
dc.subjectDRUG-RESISTANT EPILEPSY
dc.subjectP-GLYCOPROTEIN
dc.titleIs cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución